8-K: AMS Q3 Revenue Up 2.5%, EBITDA Jumps 42.3%

American Shared Hospital Services reported a 2.5% revenue increase and a 42.3% EBITDA growth for Q3 2025, driven by direct patient care services.

Summary

• Q3 2025 revenue increased 2.5% to $7.2 million, primarily from expanded radiation therapy services in the direct patient care segment.
• Direct patient care services revenue grew 9.4% in Q3 2025 to $4.0 million and 36.5% for the first nine months of 2025 to $10.7 million, driven by new physicians in Rhode Island and the Puebla, Mexico center.
• Net loss for Q3 2025 significantly decreased by 91.8% to $17,000 from a loss of $207,000 in Q3 2024.
• Adjusted EBITDA for Q3 2025 increased 42.3% to $1.94 million compared to $1.37 million in Q3 2024.
• For the first nine months of 2025, total revenue increased 5.6% to $20.4 million.
• The medical equipment leasing segment revenue decreased 5.3% in Q3 2025 to $3.1 million and 15.6% for the first nine months of 2025 to $9.7 million, due to lower PBRT volumes and Gamma Knife contract expirations.
• Net loss for the first nine months of 2025 was $0.9 million, compared to a net income of $3.5 million in the prior year, which included a $3.9 million bargain purchase gain.
• Cash, cash equivalents, and restricted cash decreased to $5.3 million at September 30, 2025, from $11.3 million at December 31, 2024, due to $7.5 million in capital expenditures.
• An existing health system signed a 10-year extension and an upgrade to their Gamma Knife System (Esprit).

Sentiment

Score: 7

Explanation: The company reported strong Q3 financial improvements with significant EBITDA growth and reduced net loss, driven by its strategic shift to direct patient care. While year-to-date net loss increased due to a prior-year one-time gain and cash decreased due to CapEx, the operational momentum, new contracts, and expansion plans indicate a positive trajectory despite some headwinds in the legacy leasing segment.

Positives

• Q3 2025 revenue increased 2.5% to $7.2 million.
• Direct patient services revenue increased 9.4% in Q3 2025 and 36.5% for the first nine months of 2025.
• Gross margin improved to 22.1% in Q3 2025, increasing 15.8% to $1.6 million.
• Net loss decreased 91.8% to $17,000 in Q3 2025.
• Adjusted EBITDA increased 42.3% to $1.94 million in Q3 2025.
• Revenue for the first nine months of 2025 increased 5.6% to $20.4 million.
• The new radiation therapy center in Puebla, Mexico, is performing strongly with significant revenue growth.
• Secured a 10-year extension and an upgrade to an Esprit Gamma Knife System with an existing health system.
• Paid down short-term debt during the quarter.
• Received Certificate of Need approvals for a first radiation therapy treatment center in Bristol, Rhode Island, and a proton beam radiation therapy treatment center in Johnston, Rhode Island.

Negatives

• Medical equipment leasing segment revenue decreased 5.3% in Q3 2025 to $3.1 million due to lower PBRT volumes.
• Medical equipment leasing segment revenue decreased 15.6% for the first nine months of 2025 to $9.7 million due to lower Gamma Knife volumes from three contract expirations since Q4 2024 and lower PBRT volumes.
• Gross margins for the first nine months of 2025 decreased to $4.2 million (20.4%) from $6.0 million, primarily due to lower treatment volumes and increased operating costs from the shift to direct patient care services, which have lower margins.
• Net loss attributable to American Shared Hospital Services for the first nine months of 2025 was $0.9 million, compared to a net income of $3.5 million in the prior year, which included a $3.9 million bargain purchase gain.
• Adjusted EBITDA for the first nine months of 2025 decreased to $4.6 million from $5.1 million in the prior year.
• Cash, cash equivalents, and restricted cash decreased by $6.0 million to $5.3 million at September 30, 2025, from $11.3 million at December 31, 2024, driven by $7.5 million in capital expenditures.
• Shareholders' equity decreased to $24.6 million or $3.77 per share at September 30, 2025, from $25.2 million or $3.92 per share at December 31, 2024.

Risks

• Risks of economic and market conditions.
• Risks of variability of financial results between quarters.
• Risks of the Gamma Knife, proton therapy, and direct patient care services businesses.
• Risks of changes to CMS reimbursement rates or reimbursement methodology.
• Risks of the timing, financing, and operations of the Company's Gamma Knife, proton therapy, and direct patient care services businesses.
• Risk of expanding within or into new markets.
• Risk that the integration or continued operation of acquired businesses could adversely affect financial results.
• Risk that current and future acquisitions may negatively affect the Company's financial position.

Future Outlook

The company expects further revenue growth from the new Esprit Gamma Knife center in Guadalajara, Mexico, starting in Q2 2026. Management anticipates continued positive trends in direct patient care services revenue into the end of 2025 and beyond, driven by strategic initiatives, new business development, and expansion in Rhode Island with new radiation therapy and proton beam centers. They believe their track record of revenue growth and improved margins positions them for long-term shareholder value.

Management Comments

• "I am pleased to report revenue increases in both our three and nine-month results which were primarily driven by increased revenue in our direct patient care services segment as our new physicians in Rhode Island ramp up and volumes increase." Gary Delanois, CEO.
• "Our new radiation therapy center in Puebla Mexico is off to a fantastic start where revenue has grown significantly." Gary Delanois, CEO.
• "As we look into the remainder of this year and 2026, we expect further growth in revenue from the new Esprit being installed in our new Gamma Knife center in Guadalajara, Mexico that is expected to startup in the second quarter of 2026." Gary Delanois, CEO.
• "We are also very pleased to announce the recent signing of an Existing Health System to a 10 Year Extension for an Esprit the latest model Gamma Knife System." Gary Delanois, CEO.
• "We believe we are well positioned for continued long-term growth with our Certificate of Need approvals for the first radiation therapy treatment center in Bristol, Rhode Island where permitting activities are underway and a proton beam radiation therapy treatment center in Johnston, Rhode Island, which will put us on track to further expand our Rhode Island footprint and growth potential." Gary Delanois, CEO.
• "Our third quarter of 2025 was highlighted by an increase in direct patient care services revenue, and we expect to see this positive trend continue into the end of the year and beyond." Scott Frech, CFO.
• "Our momentum continues to build, as we execute on our growth strategy and focus beyond our traditional medical equipment leasing model to a direct provider of radiation therapy treatment services to cancer patients." Scott Frech, CFO.
• "Our track record of consecutive years of revenue growth and improved margins is expected to position us well for building long-term shareholder value." Ray Stachowiak, Executive Chairman.

Industry Context

American Shared Hospital Services is transitioning its business model from primarily medical equipment leasing to a direct provider of advanced radiation therapy cancer treatment services. This shift aligns with a broader trend in healthcare towards integrated patient care and specialized treatment centers, particularly in oncology. The focus on Gamma Knife and proton beam therapy positions the company in high-growth, high-technology segments of cancer treatment. The expansion into direct patient care, especially in emerging markets like Mexico and underserved regions like Rhode Island, indicates a strategy to capture market share by offering comprehensive solutions and leveraging advanced technology. The decline in the traditional leasing segment highlights the importance of this strategic pivot.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through revenue growth, improved margins, and strategic expansion, but also short-term dilution of equity per share and cash reduction due to CapEx.
• Patients: Increased access to advanced cancer treatment services through new centers in Rhode Island and Mexico, and upgrades to existing Gamma Knife systems.
• Health Systems/Partners: Continued partnerships and extensions for advanced medical equipment and services, fostering integrated cancer care.
• Employees: Growth in direct patient care services may lead to increased employment opportunities, particularly for physicians and operational staff in new centers.
• Creditors: Short-term debt paid down, indicating responsible financial management, but significant capital expenditures could impact future liquidity if not managed effectively.

Next Steps

• Continue ramp-up of new physicians and volumes in Rhode Island.
• Continue growth of the new radiation therapy center in Puebla, Mexico.
• Installation of new Esprit Gamma Knife in Guadalajara, Mexico, with expected startup in Q2 2026.
• Permitting activities underway for the first radiation therapy treatment center in Bristol, Rhode Island.
• Further expansion of Rhode Island footprint with a proton beam radiation therapy treatment center in Johnston, Rhode Island.
• Focus on strategic initiatives to further improve efficiency and take advantage of economies of scale.
• Continue new business development initiatives.
• Execute on growth strategy focusing beyond traditional medical equipment leasing to direct provider of radiation therapy treatment services.
• Continue operational enhancements and cost efficiencies.

Key Dates

Recommendation

While the Q3 2025 results show strong operational improvements, particularly in direct patient care services, and a significant reduction in net loss, the year-to-date performance is mixed. The nine-month net loss and EBITDA are down compared to the prior year, largely due to a non-recurring bargain purchase gain in 2024 and the shift to lower-margin direct patient care services. Cash reserves have also significantly decreased due to capital expenditures. The strategic pivot to direct patient care and expansion plans are positive long-term drivers, but the decline in the legacy leasing segment and the impact of CapEx on cash warrant a cautious approach. Investors should monitor the execution of new projects and the sustained profitability of the direct patient care segment before a stronger recommendation.

Keywords

stereotactic radiosurgery, radiation therapy, cancer treatment, Gamma Knife, proton beam therapy, medical equipment leasing, direct patient care, healthcare services, EBITDA growth, revenue growth, SEC filing, financial results